|
Dexrazoxane
API |
|
|
|
Haorui supplies high quality Dexrazoxane API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Dexrazoxane API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
|
|
|
What is Dexrazoxane?
|
| Dexrazoxane
is used to help prevent or lessen a toxic effect to your
heart that is caused by certain medicines that are used
to treat cancer. Dexrazoxane is approved by the Food and Drug
Administration (FDA) as a protectant medicine given to
women with metastatic breast cancer who are being
treated with the chemotherapy drug doxorubicin. In most
cases these women already will have received greater
than 300 mg per square meter (mg/m2) of the
chemotherapy drug doxorubicin before dexrazoxane is
added. Dexrazoxane is given in combination with
doxorubicin. Doxorubicin can cause damage to heart
muscle and the risk of this damage increases as the
total dose increases. The addition of dexrazoxane at the
appropriate time in therapy can decrease the extent of
damage to the heart muscle.
|
|
|
|
Dexrazoxane description
|
| Dexrazoxane
is a clear, colorless solution. It is administered
intravenously, into a vein, over a 15-30 minute period.
Dexrazoxane is given within 30 minutes prior to
receiving the doxorubicin. When doxorubicin gets into
cells, it combines with iron to form toxic substances
that destroy heart muscle. Dexrazoxane interferes with
the doxorubicin binding to the iron compound so that the
toxic substance is not formed and the heart muscle is
protected.
|
|
|
|
Dexrazoxane
recommended
dosage
|
| Dexrazoxane
doses can be determined using a mathematical calculation
that measures a person's body surface area (BSA). This
number is dependent upon a patient's height and weight.
The larger the person, the greater the body surface
area. Body surface area is measured in units known as
meters squared (m2). The body surface area is
calculated and then multiplied by the drug dosage in
mg/m2. This calculates the actual dose a
patient is to receive.
|
| Dexrazoxane
is dosed in mg/m2 as a 10:1 ratio of the
doxorubicin dose. For example, if a patient is to
receive doxorubicin 50 mg/m2, then the
patient would receive dexrazoxane 500 mg/m2.
Once the dose is determined, the drug is administered
either directly into the vein over a few minutes as an
intravenous push, or as a quick infusion from an
infusion bag. This is then followed by the doxorubicin
intravenously.
|
|
|
|
Dexrazoxane
Precautions
|
| Blood
counts will be monitored regularly while on dexrazoxane
therapy. During a certain time period after receiving
chemotherapy, there is an increased risk of getting
infections. Caution should be taken to avoid unnecessary
exposure to crowds and people with infections.
|
| Patients
should not expect their doctor to use dexrazoxane the
first time they receive chemotherapy. It is thought that
dexrazoxane may interfere with the chemotherapy drug's
ability to destroy cancer cells. Dexrazoxane is
therefore only used when absolutely necessary.
|
| Patients
who may be pregnant or are trying to become pregnant
should tell their doctor before receiving dexrazoxane.
|
| Chemotherapy
can cause men and women to be sterile (not able to have
children). It is unknown if dexrazoxane causes
sterility.
|
| Patients
should check with their doctors before receiving live
virus vaccines while on chemotherapy along with
dexrazoxane.
|
|
|
| Dexrazoxane
Side
effects
|
| The
most common side effect from receiving the dexrazoxane
is pain at the injection site. Another common side
effect when dexrazoxane is given with chemotherapy is
that the blood counts fall lower than with just
chemotherapy alone. However, the time it takes for the
blood counts to return to normal is the same with or
without the dexrazoxane.
|
|
|
Low
blood counts, referred to as myelosuppression, are
expected due to chemotherapy with dexrazoxane
administration. A low white blood cell count is called
neutropenia, and patients are at an increased risk of
developing a fever and infections. Platelets are blood
cells in the body that allow for the formation of clots.
When the platelet count is low, patients are at an
increased risk for bruising and bleeding. Low red blood
cell counts, referred to as anemia, may also occur due
to chemotherapy administration. Low red counts cause
fatigue.
|
|
| Most
other side effects occur due to the administration of
the chemotherapy agents that accompany dexrazoxane.
Common side effects include nausea and vomiting.
Patients are given medicines before receiving
chemotherapy that can help prevent or decrease these
side effects from happening. Other common side effects
are hair loss (alopecia), fatigue, loss of appetite,
mouth sores, fevers, infections, diarrhea, and changes
in liver function.
|
|
| Less
common side effects are nerve damage, swelling and
inflammation of the veins where the chemotherapy is
administered, difficulty swallowing, bleeding, itching,
and skin reactions in areas of previous radiation.
|
|
|
Dexrazoxane Interactions
|
| Dexrazoxane
should only be used with chemotherapy combinations that
contain doxorubicin or other agents in the anthracycline
class of antineoplastics.
|
|
|
|
Patients should tell their doctors if they have a known
allergic reaction to dexrazoxane or any other
medications or substances, such as foods and
preservatives. Before taking any new medications,
including nonprescription medications, vitamins, and
herbal medications, the patients should notify their
doctors
|
|
|
|
Disclaimer:
|
|
Information
on this page is provided for general information
purposes. You should not make a clinical treatment
decision based on information contained in this page
without consulting other references including the
package insert of the drug, textbooks and where
relevant, expert opinion. We cannot be held responsible
for any errors you make in administering drugs mentioned
on this page, nor for use of any erroneous information
contained on this page.
|
|
|
